WO2021028005A1 - Médicament comprenant de l'anabasine pour le traitement de l'asthme, de l'allergie respiratoire et des dermatites atopiques - Google Patents

Médicament comprenant de l'anabasine pour le traitement de l'asthme, de l'allergie respiratoire et des dermatites atopiques Download PDF

Info

Publication number
WO2021028005A1
WO2021028005A1 PCT/EG2019/000032 EG2019000032W WO2021028005A1 WO 2021028005 A1 WO2021028005 A1 WO 2021028005A1 EG 2019000032 W EG2019000032 W EG 2019000032W WO 2021028005 A1 WO2021028005 A1 WO 2021028005A1
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
anabasine
chest
allergy
patients
Prior art date
Application number
PCT/EG2019/000032
Other languages
English (en)
Inventor
Mohamed Fadly Abd el Ghany ELKAZAZ
Original Assignee
Elkazaz Mohamed Fadly Abd El Ghany
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elkazaz Mohamed Fadly Abd El Ghany filed Critical Elkazaz Mohamed Fadly Abd El Ghany
Publication of WO2021028005A1 publication Critical patent/WO2021028005A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • 2- current medicament comprises of (L)(-)Anabasine as an active ingredient at 0.1 : 0.15 mg/kg of body weight and a pharmacologically acceptable excipient , diluent or carrier .
  • 3- Medicament at mentioned doses is described to be administered by oral route twice per day for a period from 30 : 40 days for asthmatics and patients of chest allergy according to severity and condition development and from 21 : 40 days for patients of atopic dermatitis according to severity and condition development .
  • medication is one course only .
  • Receptors function modulation also may last longly after removal of (L) anabasine due to the permanent loss of functional channels within prolonged desensitizationfSimasko et al.,1986;Boyd,1987; Lukas, 1991; Buisson and Bertrand, 2002 ).
  • This administering also negatively adapts signaling pathways .
  • ALL these mutations may lead to a specific cholinergic modulation of allergic effector cells.
  • this desensitization also shapes cholinergic signaling which regulates and drives skeletal muscles contraction including airways smooth muscle, which plays an integral part in the pathophysiology of asthma.
  • nicotinic acetylcholine receptors in the peripheral nervous system transmit outgoing signals from the presynaptic to the postsynaptic cells within the sympathetic and parasympathetic nervous system , Heterologous desensitization also may thereafter leads these receptors to internalization .
  • Role of receptor-mediated endocytosis is will recognized up take downregulation of transmembrane signal transduction but can also promote sustained signal transduction . It is actively implicated in transducing signals from the cell periphery to the nucleus .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un nouveau médicament oral comprenant de (L)(-)anabasine en tant que principe actif à une concentration posologique d'environ 0,1 : 0,15 mg/kg du poids corporel et un excipient, diluant ou support pharmaceutiquement acceptable. Le médicament normalise et traite l'asthme, les allergies respiratoires et la dermatite atopique, en raison de l'action agoniste complète de l'anabasine sur les récepteurs nicotiniques de l'acétylcholine.
PCT/EG2019/000032 2019-08-15 2019-12-30 Médicament comprenant de l'anabasine pour le traitement de l'asthme, de l'allergie respiratoire et des dermatites atopiques WO2021028005A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2019081276 2019-08-15
EG2019081276 2019-08-15

Publications (1)

Publication Number Publication Date
WO2021028005A1 true WO2021028005A1 (fr) 2021-02-18

Family

ID=74571262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2019/000032 WO2021028005A1 (fr) 2019-08-15 2019-12-30 Médicament comprenant de l'anabasine pour le traitement de l'asthme, de l'allergie respiratoire et des dermatites atopiques

Country Status (1)

Country Link
WO (1) WO2021028005A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015306A1 (fr) * 1991-03-01 1992-09-17 University Of Florida Utilisation des analogues nicotiniques pour le traitement des maladies degeneratives du systeme nerveux
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015306A1 (fr) * 1991-03-01 1992-09-17 University Of Florida Utilisation des analogues nicotiniques pour le traitement des maladies degeneratives du systeme nerveux
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication

Similar Documents

Publication Publication Date Title
AU2023233141A1 (en) Method of treatment with tradipitant
US10092564B2 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
US10195193B2 (en) Levocetirizine and montelukast in the treatment of inflammation mediated conditions
JP6921154B2 (ja) プラダー・ウィリー症候群を治療する方法
JP7138300B2 (ja) 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
CY1115269T1 (el) Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους
WO2021028005A1 (fr) Médicament comprenant de l'anabasine pour le traitement de l'asthme, de l'allergie respiratoire et des dermatites atopiques
CA3023836C (fr) Triple combinaison d'antagonistes purs du recepteurs 5-ht6, d'inhibiteurs de l'acetylcholinesterase et d'antagonistes du recepteur nmda
CA3023828A1 (fr) Combinaison d'antagonistes purs des recepteurs 5-ht6 et d'un antagoniste des recepteurs nmda
Dehghani Firoozabadi et al. Prevention of nausea and vomiting: methods and utility after surgery in cancer patients?
Onifer et al. Antinociceptive effects of spinal manipulative therapy on nociceptive behavior of adult rats during the formalin test
Magat et al. Oral spasmolytics
US20210393616A1 (en) Pharmaceutical compositions and methods for treating psychosis
Li et al. The protective effect of the Rho-kinase inhibitor hydroxyfasudil on propofol-induced hippocampal neuron apoptosis in neonatal rats
WO2023227881A1 (fr) Composés destinés à être utilisés dans le traitement de maladies et d'états associés à un dysfonctionnement neurodégénératif
CN111629726A (zh) 通过激活神经元异侧烟碱型乙酰胆碱受体抵抗呼吸抑制的方法
Kose 647. Oxytocin for Treating Depression: A Double Blind Placebo Controlled Neuroimaging Study
Luijendijk et al. DOES ACTIVATION OF MIDBRAIN DOPAMINE NEURONS PROMOTE OR REDUCE FEEDING?
US20140011772A1 (en) Compositions and methods for treating conditions associated with neuronal dysfunction
WO2017111052A1 (fr) Agent thérapeutique pour une maladie auto-immune
Oliveira et al. (503) Activation of encephalic neurons by Transcutaneous Electrical Nerve Stimulation (TENS) in rats
WO2009113810A3 (fr) Composition pharmaceutique, utilisation de celle-ci et procédé de traitement ou de prévention de maladies allergiques ou auto-immunes
TH93888A (fr)
WO2014187226A1 (fr) Utilisation de méfloquine lévogyre dans la préparation d'un médicament préventif contre la douleur neuropathique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19941596

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19941596

Country of ref document: EP

Kind code of ref document: A1